Inimex Achieves Milestone Targets
Inimex Pharmaceuticals is pleased to report successful completion of key 2005 R&D milestones ahead of schedule, triggering release of $4 million in funds from Series A investors. Inimex is developing first in class products that selectively modulate the innate immune response. These medicines show promise for the safe and effective treatment of a broad spectrum of serious unmet medical needs. The lead indication is for treatment of hospital pneumonia. In 2004 the company announced an $8 million Series A venture financing.
()a href="http://www.newswire.ca/en/releases/archive/June2005/15/c1727.html" target="_blank">Canada NewsWire Group